BACKGROUND: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) consist of a large heterogeneous group of epithelial tumors with neuroendocrine differentiation that arises in gastrointestinal tract and pancreatic tissues. Advanced GEP-NENs are considered distinct disease entity with limited approved treatment options and poor prognosis. So, we will explore in this systematic review the value of using bevacizumab-based combination in this subset of NENs. METHODS: PubMed, Medline, the Cochrane Library, trip database and Google Scholar were searched using the terms "GEP-NENs" OR "Gastroenteropancreatic neuroendocrine tumors" AND "systemic anticancer therapy" AND "Bevacizumab" and selecting only the English literature. Outcomes of interest included progression-free survival and overall survival (PFS and OS), tumor response and toxicities. RESULTS: A total of 17 potentially relevant trials were identified, of which eight studies were excluded. Hence, nine trials involving 320 patients were included. Median PFS was reported in eight out of the nine studies ranging from 8.2 to 16.5 months. Median OS was reported in one study, and it was 33.3 months for the whole group. The disease control rate was reported in the seven studies, and it ranged from 80 to 96%. The overall response rate was reported in eight studies, and it ranged from 0 to 64%. Frequently reported grade 3/4 toxicities were gastrointestinal toxicities, mucocutaneous toxicities and hematologic toxicities (particularly leucopenia). CONCLUSIONS: The current evidence from the available clinical trials suggests that bevacizumab in combination with some other anticancer agents (especially mTOR inhibitors and interferons) could be a more effective and tolerable treatment for advanced GEP-NENs in the future. However, such bevacizumab-based combination cannot be recommended outside the setting of clinical trials.
BACKGROUND:Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) consist of a large heterogeneous group of epithelial tumors with neuroendocrine differentiation that arises in gastrointestinal tract and pancreatic tissues. Advanced GEP-NENs are considered distinct disease entity with limited approved treatment options and poor prognosis. So, we will explore in this systematic review the value of using bevacizumab-based combination in this subset of NENs. METHODS: PubMed, Medline, the Cochrane Library, trip database and Google Scholar were searched using the terms "GEP-NENs" OR "Gastroenteropancreatic neuroendocrine tumors" AND "systemic anticancer therapy" AND "Bevacizumab" and selecting only the English literature. Outcomes of interest included progression-free survival and overall survival (PFS and OS), tumor response and toxicities. RESULTS: A total of 17 potentially relevant trials were identified, of which eight studies were excluded. Hence, nine trials involving 320 patients were included. Median PFS was reported in eight out of the nine studies ranging from 8.2 to 16.5 months. Median OS was reported in one study, and it was 33.3 months for the whole group. The disease control rate was reported in the seven studies, and it ranged from 80 to 96%. The overall response rate was reported in eight studies, and it ranged from 0 to 64%. Frequently reported grade 3/4 toxicities were gastrointestinal toxicities, mucocutaneous toxicities and hematologic toxicities (particularly leucopenia). CONCLUSIONS: The current evidence from the available clinical trials suggests that bevacizumab in combination with some other anticancer agents (especially mTOR inhibitors and interferons) could be a more effective and tolerable treatment for advanced GEP-NENs in the future. However, such bevacizumab-based combination cannot be recommended outside the setting of clinical trials.
Authors: U Plöckinger; G Rindi; R Arnold; B Eriksson; E P Krenning; W W de Herder; A Goede; M Caplin; K Oberg; J C Reubi; O Nilsson; G Delle Fave; P Ruszniewski; H Ahlman; B Wiedenmann Journal: Neuroendocrinology Date: 2005-04-18 Impact factor: 4.914
Authors: Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski Journal: N Engl J Med Date: 2011-02-10 Impact factor: 91.245
Authors: Anja Rinke; Hans-Helge Müller; Carmen Schade-Brittinger; Klaus-Jochen Klose; Peter Barth; Matthias Wied; Christina Mayer; Behnaz Aminossadati; Ulrich-Frank Pape; Michael Bläker; Jan Harder; Christian Arnold; Thomas Gress; Rudolf Arnold Journal: J Clin Oncol Date: 2009-08-24 Impact factor: 44.544
Authors: Maria P Brizzi; Alfredo Berruti; Anna Ferrero; Enrica Milanesi; Marco Volante; Federico Castiglione; Nadia Birocco; Sebastiano Bombaci; Davide Perroni; Benedetta Ferretti; Oscar Alabiso; Libero Ciuffreda; Oscar Bertetto; Mauro Papotti; Luigi Dogliotti Journal: BMC Cancer Date: 2009-11-03 Impact factor: 4.430
Authors: Elsa M Ronde; Charlotte M Heidsma; Anne M Eskes; Josefine E Schopman; Elisabeth J M Nieveen van Dijkum Journal: Eur J Cancer Care (Engl) Date: 2021-08-30 Impact factor: 2.328
Authors: Paolo Aurello; Niccolò Petrucciani; Laura Antolino; Diego Giulitti; Francesco D'Angelo; Giovanni Ramacciato Journal: World J Gastroenterol Date: 2017-05-21 Impact factor: 5.742